Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-66

Agree Zenox - they would have the data for day 56 for 15 pts at 2 weekly intervals already. They are only adding another 5 patients at that dose interval - what does that tell us? The data is clear already for that group.

They need another 5 on placebo and will do another 20 on the 1 x weekly. SO....The data being clear for that initial group -

....and the data being clear and negative they would have found a reason to dump the study and had ample opportunity to come up that reason before telling the market.

..... If the data is clear and positive - what would they do?They would want it to have max effect on pricing which they have already said. As P3 will be examining once a week dosing, they are making sure this study remains clear to apply to the end result.

If the data was inconclusive they would have either expanded the overall numbers or maybe dumped it imo.Just my 2c.

Another question.....As the data is not sealed - are PAR allowed to announce interim results if they choose to ? They have it and this SH would love to know how it went.